ATM C2488Y

CI-VAR-00000301Explore in graph →NP_000042.3:p.Cys2488TyrNM_000051.3:c.7463G>AClinVar 187037 CIViC 1172 rs774281788

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Lymphocytic Leukemia1
ATM C2488Y	Doxorubicin	Predictive	D	Supports Resistance	3	accepted	EID2849 Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the C2488Y variant on ATM expression was tested by weste… (full text at CIViC) PMID 23585524 · Navrkalova et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
187037	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Hereditary cancer-predisposing syndrome; Hereditary cancer; Ataxia-telangiectasia syndrome; Malignant tumor of breast; Familial cancer of breast; Hereditary breast ovarian cancer syndrome; Familial colorectal cancer type X	germline	17	Jun 01, 2026